Delmar Pharmaceuticals, Inc.

This study tested a new drug called VAL-083 in people with glioblastoma, an aggressive brain cancer, that had come back after standard treatments. The goal was to see if VAL-083 could help patients live longer. However, the trial was stopped early after only 2 people enrolled, so…